130 related articles for article (PubMed ID: 17146978)
1. P-value calculation for multistage phase II cancer clinical trials.
Jung SH; Owzar K; George SL; Lee T
J Biopharm Stat; 2006; 16(6):765-75; discussion 777-83. PubMed ID: 17146978
[TBL] [Abstract][Full Text] [Related]
2. On the estimation of the binomial probability in multistage clinical trials.
Jung SH; Kim KM
Stat Med; 2004 Mar; 23(6):881-96. PubMed ID: 15027078
[TBL] [Abstract][Full Text] [Related]
3. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
4. Designs for phase II trials allowing for a trade-off between response and toxicity.
Conaway MR; Petroni GR
Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
[TBL] [Abstract][Full Text] [Related]
5. Alternative designs of phase II trials considering response and toxicity.
Jin H
Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
[TBL] [Abstract][Full Text] [Related]
6. Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint.
Kovalchik S; Mietlowski W
Contemp Clin Trials; 2011 Jan; 32(1):99-107. PubMed ID: 20920605
[TBL] [Abstract][Full Text] [Related]
7. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
8. A discrete-continuous mixture quantile function estimator with a practical application to phase II cancer clinical trials.
Hutson AD
Stat Med; 2008 May; 27(12):2094-109. PubMed ID: 18038447
[TBL] [Abstract][Full Text] [Related]
9. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
10. Estimation of secondary endpoints in two-stage phase II oncology trials.
Kunz CU; Kieser M
Stat Med; 2012 Dec; 31(30):4352-68. PubMed ID: 22930470
[TBL] [Abstract][Full Text] [Related]
11. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
[No Abstract] [Full Text] [Related]
12. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
13. Methods of joint evaluation of efficacy and toxicity in phase II clinical trials.
Tournoux C; De Rycke Y; Médioni J; Asselain B
Contemp Clin Trials; 2007 Jul; 28(4):514-24. PubMed ID: 17331808
[TBL] [Abstract][Full Text] [Related]
14. Stochastically curtailed phase II clinical trials.
Ayanlowo AO; Redden DT
Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
[TBL] [Abstract][Full Text] [Related]
15. Estimation of multiple response rates in phase II clinical trials with missing observations.
Chang M
J Biopharm Stat; 2009 Sep; 19(5):791-802. PubMed ID: 20183444
[TBL] [Abstract][Full Text] [Related]
16. Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.
Kocherginsky M; Cohen EE; Karrison T
J Biopharm Stat; 2009; 19(3):524-9. PubMed ID: 19384693
[TBL] [Abstract][Full Text] [Related]
17. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
Sun X; Peng P; Tu D
Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
[TBL] [Abstract][Full Text] [Related]
18. Phase II stopping rules that employ response rates and early progression.
Goffin JR; Tu D
J Clin Oncol; 2008 Aug; 26(22):3715-20. PubMed ID: 18669457
[TBL] [Abstract][Full Text] [Related]
19. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the value of confirming responses in clinical trials in oncology.
Perez-Gracia JL; Muñoz M; Williams G; Wu J; Carrasco E; Garcia-Ribas I; Peiro A; Lopez-Picazo JM; Gurpide A; Chopitea A; Martín-Algarra S; García-Foncillas J; Blatter J
Eur J Cancer; 2005 Jul; 41(11):1528-32. PubMed ID: 16026690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
